Founded and headquartered in Dallas, Texas, in 2010, we’ve grown our capabilities to conduct our registration-enabling clinical studies in the United States, Europe, and China. Our enrolling Phase 3 clinical programs are carefully and purposefully designed to provide clear transformational cancer treatments against validated targets where only incremental advances have been made over chemotherapy in the last 20 years.
Data Driven – To date, AROG has evaluated crenolanib in over 15 completed and ongoing clinical trials in over 500 patients.
Experience Oriented– We have assembled an experienced and talented group of leaders to execute our vision.
Arog obtained exclusive worldwide rights to crenolanib and associated benzimidazole-based compounds from Pfizer following completion of early clinical studies in solid tumors in April 2010. Since then, we have discovered the FLT3 mechanism of action and have launched two Phase III clinical trials in FLT3 mutant AML.